GlassScriptPhysician profile
Khulood Rizvi
NPI 1619223104
$2,828.86
in general payments reported to CMS, 2019-2025
14 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $112 · 2021: $153 · 2022: $534 · 2023: $822 · 2024: $456 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.78 |
| Education | $194.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $831.27 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $618.49 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Shionogi INC | $471.66 | 2021-2024 | Fetroja |
| Astellas Pharma US INC | $465.62 | 2019-2024 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $103.78 | 2019 | |
| Abbvie INC. | $97.45 | 2023-2025 | Avycaz |
| Allergan, INC. | $62.11 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $59.12 | 2023-2024 | Nuzyra |
| Viiv Healthcare Company | $32.95 | 2025 | Cabenuva |
| Pfizer INC. | $21.69 | 2023 | |
| Janssen Biotech, INC. | $20.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.99 | 2021 | |
| Insmed, INC. | $14.32 | 2023 | Arikayce |
| Abbott Laboratories | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khulood Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.